Title:
FUSION PROTEIN OF ANTI-TIGIT ANTIBODY AND IL2 OR VARIANT THEREOF AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/045361
Kind Code:
A1
Abstract:
Provided are a fusion protein of an anti-TIGIT antibody and IL2 or a variant thereof, and an application thereof. Specifically, a fusion protein is provided, which comprises: (a) a first polypeptide comprising an anti-TIGIT antibody or an antigen-binding fragment thereof; and (b) a second polypeptide comprising interleukin-2 (IL-2) or a variant thereof having a lymphocyte growth promoting activity, the second polypeptide being fused to the first polypeptide. Also provided are an application of such a fusion protein in positively regulating immune cell activity and/or improving immune responses; and/or, an application thereof in the treatment of cancer, immunodeficiency or inflammatory diseases, or infectious diseases.
Inventors:
CHEN YI (CN)
CAI ZELING (CN)
HE QIAOQIAO (CN)
WANG YALING (CN)
CAI ZELING (CN)
HE QIAOQIAO (CN)
WANG YALING (CN)
Application Number:
PCT/CN2022/093346
Publication Date:
March 30, 2023
Filing Date:
May 17, 2022
Export Citation:
Assignee:
SHANGHAI CELGEN BIO PHARMACEUTICAL CO LTD (CN)
International Classes:
C07K19/00; A61K38/20; A61K39/395; A61K47/68; A61P35/00; C07K14/55; C07K16/28; C07K16/30; C12N15/13; C12N15/62
Domestic Patent References:
| WO2020249003A1 | 2020-12-17 |
Foreign References:
| US20200188526A1 | 2020-06-18 | |||
| US20190062395A1 | 2019-02-28 | |||
| US20210230242A1 | 2021-07-29 | |||
| US11028172B1 | 2021-06-08 |
Other References:
SHAO, RONGGUANG: "Monoclonal Antibody- Based Cancer Immunotherapy", ACTA PHARMACOLOGICA SINICA, NATURE PUBLISHING GROUP, GB, vol. 55, no. 6, 30 June 2020 (2020-06-30), GB , pages 1110 - 1118, XP009537351, ISSN: 1671-4083
HOOGI SHIRAN, EISENBERG VASYL, MAYER SHIMRIT, SHAMUL ASTAR, BARLIYA TILDA, COHEN CYRILLE J.: "A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 7, no. 1, 1 December 2019 (2019-12-01), XP093054400, DOI: 10.1186/s40425-019-0721-y
HOOGI SHIRAN, EISENBERG VASYL, MAYER SHIMRIT, SHAMUL ASTAR, BARLIYA TILDA, COHEN CYRILLE J.: "A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 7, no. 1, 1 December 2019 (2019-12-01), XP093054400, DOI: 10.1186/s40425-019-0721-y
Attorney, Agent or Firm:
SHANGHAI PATENT & TRADEMARK LAW OFFICE, LLC (CN)
Download PDF: